Drugs / Loteprednol
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01721694 | Dec 2012 → Mar 2013 | bacterial conjunctivitis, blepharitis, keratitis | Adapt Produtos Oftalmológicos Ltda. | Withdrawn | No outcome recorded |
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT07671222 Comparator | Dec 2026 → Mar 2028 expected | Sjogren syndrome, dry eye syndrome | Instituto de Oftalmología Fundación Conde de Valenciana | Not yet recruiting | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT02974387 Comparator | Apr → Aug 2017 | — | Dr Salouti Eye Research Center | Unknown | No outcome recorded |
| Phase 4 | NCT01456780 Comparator | Aug 2011 → Mar 2013 | blepharitis | Massachusetts Eye and Ear Infirmary | Completed | No outcome recorded |
| Phase 4 | NCT01193504 Comparator | Sep 2010 → Oct 2012 | cataract | Innovative Medical | Unknown | No outcome recorded |
| Phase 4 | NCT00817557 Comparator | Jan → Jun 2009 | — | Hom, Milton M., OD, FAAO | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Loteprednol | “Randomized, Masked Comparison of Bromfenac and Besifloxacin BID With Either Prednisolone BID or Loteprednol 0.5% BID for Prevention of Retinal Thickening and CME Following...” NCT01193504 ↗ |
| Known as | Lotemax | “Loteprednol (Lotemax)” NCT02974387 ↗ |
| Action | Inhibit | “Loteprednol inhibits processes in the body that cause inflammation.” NCT01456780 ↗ |
| Modality | Other / unclassified | “steroid agents” NCT02974387 ↗ |
| Route | Topical | “Lotemax eye drops” NCT01193504 ↗ |